Minimizing levodopa titration period for Parkinson’s disease (PD)
Objective: Develop an optimization algorithm that individualizes the pharmacokinetics-pharmacodynamics (PKPD) infusion models of levodopa, to improve the efficacy of dose titration and reduce the number…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Levodopa, placebo and rotigotine change biomarker levels for oxidative stress
Objective: The objective was to investigate the influence of the D1 receptor agonists levodopa and rotigotine compared with placebo on homocysteine and cysteinyl-glycine in plasma…Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease diagnosis
Objective: To evaluate the diagnostic value of combined acute levodopa challenge and olfactory testing to predict PD diagnosis. Background: Acute levodopa challenge can be used…Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?
Objective: The aim of this study was to explore the angiogenetic hypothesis for Levodopa-induced-dyskinesia (LID) using advanced MRI methods in patients with Parkinson's disease (PD).…Dopaminergic and non-dopaminergic effects on instrumented timed up and go test in patients with Parkinson’s disease
Objective: To evaluate an instrumented version of Timed Up and Go Test (iTUG) in patients with Parkinson's disease (PD), both in L-dopa OFF and ON-state.…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves
Objective: Idiopathic Parkinson's disease (IPD) is a chronic neurodegenerative disorder. Most of the clinicians believe that it is limited with motor and cognitive disorders. However,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.